Literature DB >> 26612848

FGF23-Associated Tumor-Induced Osteomalacia in a Patient With Small Cell Carcinoma: A Case Report and Regulatory Mechanism Study.

Adrienne Sauder1, Szymon Wiernek2, Xumin Dai2, Renata Pereira3, Michael Yudd4, Charvi Patel1, Andrew Golden1, Shahida Ahmed4, Jin Choe4, Victor Chang4, Slawomir Sender4, Donghong Cai5.   

Abstract

Tumor-induced osteomalacia (TIO) is typically caused by phosphaturic mesenchymal tumor (PMT) that secretes the phosphaturic hormone, fibroblast growth factor-23 (FGF23), resulting in decreased phosphate reabsorption in kidneys, hypophosphatemia, and finally osteomalacia. Rare cases of malignant tumor manifesting with TIO other than PMT had been reported, although in most of these reports, except one, circulating FGF23 levels were not evaluated and tissue expressing of FGF23 was not confirmed. In this article, we report a case of TIO in a patient with pulmonary small cell carcinoma with liver metastasis. The patient manifested with hypophosphatemia. His circulating level of FGF23 was markedly increased. The expression of FGF23 in tumor cells was confirmed. Furthermore, the regulatory mechanism of FGF23 in this patient was also investigated.
© The Author(s) 2015.

Entities:  

Keywords:  FGF23; small cell carcinoma; tumor-induced osteomalacia; wnt signaling pathway

Mesh:

Substances:

Year:  2015        PMID: 26612848     DOI: 10.1177/1066896915617828

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  6 in total

Review 1.  Tumor-Induced Osteomalacia.

Authors:  Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

Review 2.  Phosphaturic mesenchymal tumors: what an endocrinologist should know.

Authors:  J M Boland; P J Tebben; A L Folpe
Journal:  J Endocrinol Invest       Date:  2018-02-14       Impact factor: 4.256

3.  A Case Report of Hypophosphatemia Leading to the Diagnosis of Mesothelioma.

Authors:  Zi W Goh; Faisal Hasan
Journal:  Cureus       Date:  2022-05-24

4.  Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.

Authors:  Nobuaki Ito; Takuo Kubota; Sachiko Kitanaka; Ikuma Fujiwara; Masanori Adachi; Yasuhiro Takeuchi; Hitomi Yamagami; Takehide Kimura; Tatsuya Shinoda; Masanori Minagawa; Ryo Okazaki; Keiichi Ozono; Yoshiki Seino; Seiji Fukumoto
Journal:  J Bone Miner Metab       Date:  2021-07-13       Impact factor: 2.626

5.  Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature.

Authors:  Constantinos Savva; Jason Adhikaree; Srinivasan Madhusudan; Kamal Chokkalingam
Journal:  J Diabetes Metab Disord       Date:  2019-03-22

6.  FGF23 and Fetuin-A Interaction in the Liver and in the Circulation.

Authors:  Deborah Mattinzoli; Masami Ikehata; Koji Tsugawa; Carlo M Alfieri; Paola Dongiovanni; Elena Trombetta; Luca Valenti; Aldamaria Puliti; Lorenza Lazzari; Piergiorgio Messa
Journal:  Int J Biol Sci       Date:  2018-04-25       Impact factor: 6.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.